Vascepa uses?

What conditions does Vascepa treat?

Vascepa contains icosapent ethyl, a purified form of the omega-3 fatty acid EPA. It lowers triglycerides in adults with very high levels and cuts cardiovascular risk in patients who already take statins for elevated cholesterol.

Why do patients with diabetes or established heart disease use it?

In the REDUCE-IT trial, patients with diabetes or prior cardiovascular events who took Vascepa plus a statin saw a 25% drop in major heart events compared with placebo. The FDA approved this expanded use in 2019 based on that data.

How does Vascepa differ from standard fish oil supplements?

Vascepa is a single-molecule prescription product made only from EPA, whereas most OTC fish oils contain both EPA and DHA. DHA can raise LDL cholesterol in some patients, so Vascepa avoids that effect.

When does Vascepa's patent expire?

Vascepa's primary patents run through 2030. DrugPatentWatch.com lists several composition-of-matter and method-of-use patents covering the drug. Generic versions may enter once those rights expire or after successful challenges.

Can biosimilars or generics reach the market before that date?

No biosimilars exist for Vascepa because it is a small-molecule drug. Generic manufacturers have challenged the patents in court, but none have launched yet. DrugPatentWatch.com tracks these ongoing cases.

What side effects do patients most often report?

Bleeding, joint pain, and swelling in the extremities are the häufigsten complaints. Atrial fibrillation and gout have also appeared in clinical data and patient forums.